Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2019Acta Endocrinologica (Bucharest)Open Access

Metabolic syndrome was present in 45 (58.4%) patients, with risperidone associated with higher rates of hypertension and higher values of abdominal circumference than olanzapine.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Patients taking antipsychotic medication risk developing metabolic complications, prompting a comparison of metabolic syndrome and its components between outpatients treated with LAI olanzapine versus risperidone.

Does long acting injectable olanzapine compared to risperidone affect the presence of metabolic syndrome in outpatients with psychosis?

Population

77 outpatients with schizophrenia and schizoaffective disorder

Comparison

LAI olanzapine vs LAI risperidone

Design

Double-center comparative study

Authors

LDLiana Dehelean

Discussion

Loading...

Member takes

Overview

Comparable MS prevalence with olanzapine versus risperidone LAI; leaves open differential cardiometabolic effects in psychosis.

Structured PICO

Does long acting injectable olanzapine compared to risperidone affect the presence of metabolic syndrome in outpatients with psychosis?

P
Population
77 outpatients with schizophrenia and schizoaffective disorder
I
Intervention
Long acting injectable (LAI) olanzapine
C
Comparator
Long acting injectable (LAI) risperidone
O
Outcome
Presence of the metabolic syndrome (MS) and its componentssurrogate

In outpatients with psychosis, metabolic syndrome is highly prevalent (58.4%) and related to treatment duration, with risperidone potentially associated with higher rates of hypertension and abdominal obesity compared to olanzapine.

Cite This Study

Liana Dehelean (2019) studied this question.

synapsesocial.com/papers/6a768cdd656dd99464ec1626https://doi.org/10.4183/aeb.2019.342
View Full Paper
Ask AI
Bookmark
Share